Drug
Perifosine clinical trials
Also written KRX-0401.
- studies test it
- 37
- open now
- 0
- in phase 3
- 2
- first study started
- 1999
How studies write it
Studies that test it under each name
Development codes
- KRX-0401
- 12
Combined with it in one product
Studies by the year they started
37 studies that test it; most in 2003 (9)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 1 |
| 2003 | 9 |
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 9 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 3 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 22
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 19
AEterna Zentaris (18) · National Cancer Institute (NCI) (7) · Memorial Sloan Kettering Cancer Center (3) · NCIC Clinical Trials Group (2) · University Health Network, Toronto (2) · University of Wisconsin, Madison (1) · Dana-Farber Cancer Institute (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Temsirolimus (2) · Capecitabine (1) · Imatinib (1) · Docetaxel (1) · Sorafenib (1) · Sunitinib (1) · Paclitaxel (1) · Gemcitabine (1)
Studies
Open first, then newest update. How each study uses perifosine is read from its arms, and is right about nine times in ten.
Testing it · 37
- Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue SarcomaCompletedPhase 2NCIC Clinical Trials GroupNCT00053794Written as perifosine
- Perifosine in Treating Patients With Metastatic or Recurrent Malignant MelanomaCompletedPhase 2NCIC Clinical Trials GroupNCT00053781Written as perifosine
- Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedPhase 1/2National Cancer Institute (NCI)NCT01051557Written as Perifosine
- Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant GliomasCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00590954Written as Perifosine
- Perifosine in Treating Patients With Advanced Solid TumorsCompletedPhase 1University of Wisconsin, MadisonNCT00005794Written as perifosine
- Study of Perifosine + Capecitabine for Colon Cancer PatientsCompletedPhase 1AEterna ZentarisNCT01048580Written as Perifosine
- A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's MacroglobulinemiaCompletedPhase 2AEterna ZentarisNCT00398710Written as Perifosine
- Phase II Study of Perifosine in Patients With Refractory and Relapsed LeukemiaCompletedPhase 2AEterna ZentarisNCT00391560Written as perifosine
- A Food Effect and QTc Study of Perifosine in Patients With Advanced MalignanciesCompletedPhase 1AEterna ZentarisNCT01224730Written as perifosine
- Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer PatientsCompletedPhase 2AEterna ZentarisNCT00398879Written as Perifosine
- A Trial of Perifosine in Patients With Chemo-Insensitive SarcomasCompletedPhase 2AEterna ZentarisNCT00401388Written as Perifosine
- Trial of Two Schedules of Perifosine for Patients With Solid Tumors or LymphomasCompletedPhase 2AEterna ZentarisNCT00389077Written as Perifosine
- A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal CancerCompletedPhase 2AEterna ZentarisNCT00448721Written as Perifosine
- A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung CancerCompletedPhase 1/2AEterna ZentarisNCT00399789Written as Perifosine
- Ph II Study of Perifosine Plus Gleevec for Patients With GISTCompletedPhase 2AEterna ZentarisNCT00455559Written as Perifosine
- Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma PatientsTerminatedPhase 3AEterna ZentarisNCT01002248Written as Perifosine
- Ph II Study of Perifosine for Patients With Carcinoma of the KidneyCompletedPhase 2AEterna ZentarisNCT00498966Written as Perifosine
- Perifosine in Patients With Relapsed/Refractory Waldenstrom's MacroglobulinemiaCompletedPhase 2Dana-Farber Cancer InstituteNCT00422656Written as Perifosine
- Study of Single Agent Perifosine for Recurrent Pediatric Solid TumorsCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00776867Written as perifosine
- Perifosine With Temsirolimus for Recurrent Pediatric Solid TumorsCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT01049841Written as perifosine + temsirolimus
See all 37 studies that test perifosine →
Given in every arm · 5 — perifosine is usual care beside what is tested
- Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant GliomasCompletedPhase 1Andrew B Lassman, MDNCT02238496Written as Perifosine
- Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple MyelomaCompletedNot applicableAEterna ZentarisNCT00847366Written as Perifosine
- Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple MyelomaCompletedPhase 2AEterna ZentarisNCT00375791Written as perifosine
- Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma PatientsCompletedPhase 1/2AEterna ZentarisNCT00401011Written as Perifosine
- Phase I Trial of Docetaxel With PerifosineCompletedPhase 1AEterna ZentarisNCT00399087Written as Perifosine
Codes
What other systems call perifosine · ClinicalTrials.gg INT003980
- MeSH (NLM) C105905perifosineOne source NLM
- UNII (FDA) 2GWV496552PERIFOSINEConfirmed FDA, NLM, Wikidata
- Wikidata Q3411917perifosineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1727PerifosineOne source FDA
- DrugBank DB06641One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C105905 | perifosine | One source NLM |
| UNII (FDA) | 2GWV496552 | PERIFOSINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3411917 | perifosine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1727 | Perifosine | One source FDA |
| DrugBank | DB06641 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.